InspireMD (NSPR) COO receives 226,695 restricted stock shares in grant

Rhea-AI Filing Summary

InspireMD, Inc. reported that Chief Operating Officer Andrea Tommasoli received an award of 226,695 shares of common stock on January 14, 2026. The shares were acquired at a price of $0 per share, indicating a grant of restricted stock rather than an open-market purchase. Following this grant, Tommasoli beneficially owned 954,389 shares of InspireMD common stock directly.

According to the footnote, these shares are restricted stock that vest in three equal annual installments, with one-third scheduled to vest on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to Tommasoli’s continued service with the company. This structure ties a portion of the executive’s compensation to ongoing employment and future share value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tommasoli Andrea

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		A		226,695(1)	A	$0	954,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to the Reporting Person's continued service.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Andrea Tommasoli	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) disclose for January 14, 2026?

The company disclosed that Chief Operating Officer Andrea Tommasoli acquired 226,695 shares of InspireMD common stock on January 14, 2026 through a restricted stock grant priced at $0 per share.

How many InspireMD (NSPR) shares does Andrea Tommasoli own after this transaction?

After the reported transaction, Andrea Tommasoli beneficially owns 954,389 shares of InspireMD common stock directly.

What type of equity did InspireMD grant to its COO Andrea Tommasoli?

InspireMD granted restricted common stock to COO Andrea Tommasoli. The filing notes that the 226,695 shares are restricted stock subject to a multi-year vesting schedule.

What is the vesting schedule for Andrea Tommasoli’s restricted InspireMD shares?

The restricted stock vests in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to Tommasoli’s continued service.

Did Andrea Tommasoli pay cash for the newly acquired InspireMD shares?

No cash was paid for these shares. The filing lists a transaction price of $0 per share, indicating the shares were granted as equity compensation rather than purchased on the open market.

Is this InspireMD Form 4 filing for direct or indirect ownership?

The Form 4 indicates that the 954,389 shares held after the transaction are owned directly (D) by Andrea Tommasoli, with no separate indirect ownership entity listed.